Trpti is Saanroo’s bioavailable form of OEA, powered by LipiSperse technology developed for modern gut and metabolic health applications. Endogenous OEA production is naturally reduced in states of overweight and obesity, meaning Trpti helps replenish depleted levels of this natural satiety and metabolic signalling molecule. OEA has been described as a signalling molecule that activates peroxisome proliferator-activated receptor-α (PPAR-α), which, in turn, promotes lipolysis (the breakdown of fat) and curbs food intake. Additionally, OEA stimulates GLP-1 release via a G protein-coupled receptor (GPR119)- dependent mechanism, further aiding in reducing food intake. The published study validated this mechanism, demonstrating a notable upward trend in GLP-1 concentrations at the 6-week and 12-week marks.
In the randomised, double-blind, placebo-controlled trial, 57 overweight adults (BMI 30–40 kg/m²) received either 300 mg/day of Trpti (providing 250 mg/day OEA) or placebo for 12 weeks. Across the 12-week intervention, Trpti selectively targeted beneficial bacteria without disrupting the overall stability of the microbiome. While overall microbial diversity remained stable, Trpti supplementation supported selective, health-relevant compositional shifts. Findings included:
- Significant weight improvement in specific subgroups: In participants with a BMI under 35, Trpti supplementation led to a statistically significant reduction in body weight compared to the placebo.
- Trpti supplementation significantly enriched Akkermansia muciniphila compared to placebo. This species is increasingly recognised for its potent metabolic benefits, known for supporting mucosal integrity and glucose metabolism.
- Boost in beneficial bacteria: Increased Faecalibacterium prausnitzii in the Trpti group, a major butyrate-producing bacteria linked to healthy inflammatory effects and gut health.
- Targeted immune and barrier support: Trpti promoted an early positive immune response with increased IL-2 and reduced IL-1β at Week 6, followed by long-term improvements in gut barrier integrity markers, specifically increased circulating occludin at Week 12.
"This study demonstrates that supplementation with Trpti, Saanroo’s bioavailable form of OEA, helps maintain a healthy microbiome. Trpti supplementation showed enrichment of beneficial species, notably Akkermansia muciniphila and Faecalibacterium prausnitzii, linked to improved gut barrier function, metabolic health, and anti-inflammatory activity,” said Ramasamy Venkatesh, Managing Director at Saanroo/Gencor Pacific. “Trpti supplementation promoted a more favorable gut microbiome signature and microbial functional capacity, with trends toward modest metabolic benefits, while maintaining safety and tolerability."
To learn more about Trpti, its applications, and Saanroo’s portfolio of clinically validated ingredients, visit Saanroo.com or contact info@saanroo.com.
